Too Many Concerns, Too Little Revenue: Unilife Corp. Analyst Report by BrokerBank Securities, Inc.

NEW YORK, May 20, 2014 /PRNewswire/ -- Unilife Corporation UNIS Industry surveys and reports estimate that the overall global injectable drug delivery systems market will grow at a compound annual growth rate (CAGR) of approximately 11% through 2019, at which time the market will be valued at nearly $19 billion. Prefilled syringes represent one of the fastest growing segments among the injectable drug delivery devices market mostly due to their ease of administration, reduced risk of cross contamination, less overfill, and ease of handling. In fact, Transparency Market Research estimates that the prefilled syringe market will grow at a CAGR of roughly 13.3% for the next several years to reach an estimated value of $5 billion in 2019. Furthermore, while the prefilled syringe market today is still relatively small (worth around $2.5 billion), it represents nearly one-quarter of the current total injectable drug delivery systems market.

Unilife Corporation (UNIS) designs, develops, manufacturers and commercializes injectable drug delivery systems in the United States and internationally. The company markets and sells its products to pharmaceutical and biotechnology companies who seek to leverage their differentiated and customizable devices in a format where they can be filled and packaged with an injectable therapy prior to its shipment to the end-user for safe, simple and convenient administration. Unilife's product portfolio and technology platforms cover the following medical device categories: prefilled syringes; drug reconstitution delivery systems; auto-injectors; wearable injectors; ocular delivery systems; and novel delivery systems.

A full in-depth analyst report on UNIS that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/UNIS-CFA-REPORT

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mike Maggi, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the full analyst report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapir.com. For any urgent concerns or inquiries please contact us at admin@smallcapir.com.   

CFA^® and Chartered Financial Analyst^® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.